Video

Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Wakelee discusses a study in which the researchers investigated whether a mutation enrichment next-generation sequencing could improve mutation detection in plasma and urine from the TIGER-X trial, which was a phase 1/2 study of rociletinib in patients with EGFR mutation-positive advanced NSCLC.

Of 174 matched tissue, plasma and urine specimens, 145 (83.3%) were found to be positive for the T790M mutation by central tissue testing, 142 (81.6%) of which were positive by plasma, and 139 (79.9%) positive by urine. Urine and plasma combined identified 165 cases (94.8%) as T790M-positive.

This combination of urine and plasma testing may be considered before tissue testing in EGFR TKI resistant NSCLC, including patients without extrathoracic metastases.

<<<

View more from the IASLC 17th World Conference on Lung Cancer

Related Videos
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
R. Wendel Naumann, MD, professor and director of gynecologic oncology research, and associate medical director of clinical trials, Levine Cancer Institute, Atrium Health